Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzohydroxamate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 known ✓ | Q9BY41 | 11/20 | 0.95 |
| ▸ | HDAC1 known ✓ | Q13547 | 9/20 | 0.95 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 9/20 | 0.95 |
| ▸ | HDAC2 known ✓ | Q92769 | 4/20 | 0.95 |
| ▸ | HDAC3 known ✓ | O15379 | 2/20 | 0.95 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 2/20 | 0.95 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.95 |
| ▸ | CA1 | P00915 | 1/20 | 0.95 |
| ▸ | IDO1 | P14902 | 1/20 | 0.95 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.95 |
| ▸ | CA9 | Q16790 | 1/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.95 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21755109 | 0.97 | HDAC8 (1.00) | HDAC8HDAC1HDAC6HDAC2HDAC3 | |
| Benzohydroxamate SCHEMBL28895973 | 0.97 | HDAC8 (1.00) | HDAC8HDAC1HDAC6HDAC2HDAC3 | |
| Benzohydroxamate SCHEMBL28299068 | 0.97 | HDAC8 (1.00) | HDAC8HDAC1HDAC6HDAC2HDAC3 | |
| Benzohydroxamate SCHEMBL133061 | 0.97 | HDAC8 (1.00) | HDAC8HDAC1HDAC6HDAC2HDAC3 | |
| Benzohydroxamate SCHEMBL11883624 | 0.95 | HDAC8 (0.95) | HDAC8HDAC1HDAC6HDAC2HDAC3 | |
| Benzohydroxamate SCHEMBL8660923 | 0.95 | HDAC8 (0.95) | HDAC8HDAC1HDAC6HDAC2HDAC3 | |
| Benzohydroxamate SCHEMBL6419261 | 0.95 | HDAC8 (0.95) | HDAC8HDAC1HDAC6HDAC2HDAC3 | |
| Benzohydroxamate SCHEMBL21630417 | 0.95 | HDAC8 (0.95) | HDAC8HDAC1HDAC6HDAC2HDAC3 | |
| Benzohydroxamate SCHEMBL11881231 | 0.95 | HDAC8 (0.95) | HDAC8HDAC1HDAC6HDAC2HDAC3 | |
| Benzohydroxamate SCHEMBL10875530 | 0.95 | HDAC8 (0.95) | HDAC8HDAC1HDAC6HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463735-B2 | Method and apparatus for adjusting corneal curvature through digital corneal crosslinking | ZHEJIANG UNIVERSITY (CN) | 2019-11-05 | — | — | US | claimed |
| US-20180050104-A1 | METHOD AND APPARATUS FOR ADJUSTING CORNEAL CURVATURE THROUGH DIGITAL CORNEAL CROSSLINKING | ZHEJIANG UNIVERSITY | 2018-02-22 | — | — | US | claimed |
| CN-113166105-B | Heterocyclic compounds as CDK-HDAC dual pathway inhibitors | 杭州英创医药科技有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118619922-A | Hydroxamic acid compound, and preparation method and application thereof | 郑州大学 | 2024-09-10 | — | — | CN | disclosed |
| US-10463735-B2 | Method and apparatus for adjusting corneal curvature through digital corneal crosslinking | ZHEJIANG UNIVERSITY (CN) | 2019-11-05 | — | — | US | disclosed |
| CN-109867660-A | Tetrahydroisoquinoline amide compound and its medicinal usage containing quaternary ammonium ion | 四川科伦博泰生物医药股份有限公司 | 2019-06-11 | — | — | CN | disclosed |
| CN-105814037-B | N1- (the fluoro- 2- hydroxy-2-methyl propiono of 3,3,3- tri-)-piperidine derivative of inhibitor as pyruvic dehydrogenase kinase | 默克专利股份公司 | 2018-11-30 | — | — | CN | disclosed |
| US-20180050104-A1 | METHOD AND APPARATUS FOR ADJUSTING CORNEAL CURVATURE THROUGH DIGITAL CORNEAL CROSSLINKING | ZHEJIANG UNIVERSITY | 2018-02-22 | — | — | US | disclosed |
| US-9580444-B2 | Polycyclic pyrazolinone derivative and herbicide comprising same as effective component thereof | SAGAMI CHEMICAL RESEARCH INSTITUTE (JP) | 2017-02-28 | — | — | US | disclosed |
| US-20160024110-A1 | POLYCYCLIC PYRAZOLINONE DERIVATIVE AND HERBICIDE COMPRISING SAME AS EFFECTIVE COMPONENT THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| EP-2975040-A1 | POLYCYCLIC PYRAZOLINONE DERIVATIVE AND HERBICIDE COMPRISING SAME AS EFFECTIVE COMPONENT THEREOF | Sagami Chemical Research Institute (JP) | 2016-01-20 | — | — | EP | disclosed |
| CN-1049660-A | Aminoketone derivative and application thereof | MITZUI TOATSU CHEMICALS INC (JP) | 1991-03-06 | — | — | CN | disclosed |
| EP-0414391-A2 | Aminoketone derivatives and use thereof | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1991-02-27 | — | — | EP | disclosed |
| US-4994474-A | Hypotensive agents | SANOFI (FR) | 1991-02-19 | — | — | US | disclosed |
| EP-0302792-A2 | Alkylaminoalkoxyphenyl derivatives, process of preparation and compositions containing the same | SANOFI (FR) | 1989-02-08 | — | — | EP | disclosed |
| EP-0302793-A2 | Aralkylaminoalkoxyphenyl derivatives, process of preparation and compositions containing the same | ELF SANOFI (FR) | 1989-02-08 | — | — | EP | disclosed |
| US-4376862-A | INTERMEDIATE FOR ISOXAZOLO (5,4B) PYRIDINE | LONZA LTD. (CH) | 1983-03-15 | — | — | US | disclosed |
| US-4350816-A | REACTING 3-AMINO-2,4-DICYANOCROTONIC ACID METHYL ESTER WITH A BENZOHYDROXYAMINO ACID CHLORIDE | LONZA LTD. (CH) | 1982-09-21 | — | — | US | disclosed |
| US-4172079-A | Preparation of 4-nitroisoxazoles | TEXACO INC. (US) | 1979-10-23 | — | — | US | disclosed |
| US-3960862-A | PHARMACOLOGICAL USE | BASF AKTIENGESELLSCHAFT (DT) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024110-A1 | POLYCYCLIC PYRAZOLINONE DERIVATIVE AND HERBICIDE COMPRISING SAME AS EFFECTIVE COMPONENT THEREOF | DDT, PDHX, CYP4X1 | HDAC8 2437/4885HDAC1 755/4885HDAC6 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.